Independent Peptide Analysis
Evidence-based analysis, vendor accountability, and honest guidance in a market flooded with marketing claims. No vendor sponsorship. No pay-for-play reviews.
FDA still hasn't published peptide reclassification 29 days after RFK announcement. NPR coverage drives new audience. SAFE Drugs Act bill text on Congress.gov.
Independent guide to buying BPC-157 in 2026. Grey-market vendors rated, compounding pharmacy options, and what the FDA reclassification means for access.
Complete guide to buying peptides in 2026. Grey-market vendors rated, compounding pharmacy pathways, telehealth options, and what the reclassification means.
Guide to legal semaglutide access in 2026. FDA-approved Ozempic, Wegovy, Oral Wegovy ($149/mo), and why grey-market semaglutide should be avoided.
Peptide Sciences shuts down. The FDA still hasn't published reclassification. The SAFE Drugs Act threatens the RUO model.
Oral BPC-157 vendors rated on transparency, third-party testing, value, and regulatory compliance. Updated quarterly.
Ratings reflect our independent analysis. Vendors cannot pay to improve their scores. See our methodology.
Evidence-rated profiles for every major peptide. What the research shows, what it doesn't, and what vendors won't tell you.
Weekly analysis of the peptide market: regulatory changes, vendor evaluations, research updates, and the news that matters. Zero vendor influence.